Lowell, MA – According to filings with the U.S. Securities and Exchange Commission, Alcyone Lifesciences is raising $19,458,809.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, PJ Anand played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alcyone Lifesciences

Alcyone Genetic Therapies is focused on bringing life-changing treatments for CNS genetic disorders. At Alcyone, we are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from oncolytic and chronic neurological conditions.

To learn more about Alcyone Lifesciences, visit http://www.alcyonels.com/

Contact:
PJ Anand, President and Chief Executive Officer
978-709-1946
https://www.linkedin.com/in/pj-anand-424747/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved